Skip to main content

Dr. Evan C. Chen, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
10
In the NPI registry since
2016
Medicare patients seen, 2024
93

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2016Medical school: Stanford University School of Medicine
  • 2016Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MA license 278136

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
93
Services billed
322
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes17435
Established patient office or other outpatient visit, 30-39 minutes9328
Established patient office or other outpatient visit, 40-54 minutes3521
New patient office or other outpatient visit, 60-74 minutes2929
Hospital discharge day management, 30 minutes or less1212

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 21 payments worth $20,716 in total to this clinician.

By company
Merck Sharp & Dohme LLC$10,102
Syndax Pharmaceuticals, Inc.$6,211
Autolus Inc$3,719
Rigel Pharmaceuticals, Inc.$685
By type
Consulting Fee$14,902
Honoraria$3,545
Travel and Lodging$1,527
Food and Beverage$743

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$4,800
Mar 26, 2025Merck Sharp & Dohme LLC
Mar 26, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$3,965
Dec 5, 2025Autolus Inc
Dec 5, 2025
Honoraria
in-kind
$2,860
Oct 29, 2025Merck Sharp & Dohme LLC
Oct 29, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionProvided as part of a clinical research engagement.
$1,586
Aug 18, 2025Merck Sharp & Dohme LLC
Aug 18, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$1,403
Jul 2, 2025Merck Sharp & Dohme LLC
Jul 2, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$1,135
Jun 4, 2025Merck Sharp & Dohme LLC
Jun 4, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$915
Sep 3, 2025Merck Sharp & Dohme LLC
Sep 3, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$793
Sep 5, 2025Rigel Pharmaceuticals, Inc.
Sep 5, 2025
Honoraria
Rezlidhia · Acute Myeloid Leukemia
$685
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind
$591
All 16 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 5, 2025Autolus Inc
Dec 5, 2025
Honoraria
in-kind
$2,860
Dec 5, 2025Autolus Inc
Dec 5, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$341
Dec 5, 2025Autolus Inc
Dec 5, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$300
Oct 29, 2025Merck Sharp & Dohme LLC
Oct 29, 2025
Consulting Fee
WINREVAIR · CARDIOVASCULAR
Company’s descriptionProvided as part of a clinical research engagement.
$1,586
Sep 5, 2025Rigel Pharmaceuticals, Inc.
Sep 5, 2025
Honoraria
Rezlidhia · Acute Myeloid Leukemia
$685
Sep 3, 2025Merck Sharp & Dohme LLC
Sep 3, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$793
Aug 18, 2025Merck Sharp & Dohme LLC
Aug 18, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$1,403
Aug 13, 2025Merck Sharp & Dohme LLC
Aug 13, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$305
Jul 2, 2025Merck Sharp & Dohme LLC
Jul 2, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$1,135
Jun 4, 2025Merck Sharp & Dohme LLC
Jun 4, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$915
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$4,800
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind
$591
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind
$184
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind
$79.83
May 3, 2025Syndax Pharmaceuticals, Inc.
May 3, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL
$32.00
Mar 26, 2025Merck Sharp & Dohme LLC
Mar 26, 2025
Consulting Fee
Company’s descriptionProvided as part of a clinical research engagement.
$3,965

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $51,634 in research payments for these studies, mostly to the institutions running them.

  • TAK-012-1501
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 6, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1679929574. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.